Rating Change
Leerink Partners analysts downgraded Bristol-Myers Squibb Company (NYSE:BMY) from Outperform to Market Perform on October 05, 2026.
downgradeNYSE:BMY
Bristol-Myers Squibb Company (BMY) Downgraded to Market Perform by Leerink Partners
Leerink Partners analysts downgraded Bristol-Myers Squibb Company (NYSE:BMY) from Outperform to Market Perform on October 05, 2026.
At publication ·
What changed
Bristol-Myers Squibb Company (NYSE:BMY) · downgrade
- Firm
- Leerink Partners
- Rating
- Outperform to Market Perform
- Price at event
- $58.72
- Market capitalization
- $104.2B
At a glance
Key takeaways
- Leerink Partners downgraded Bristol-Myers Squibb from Outperform to Market Perform on October 5, 2026.
Market Context
Bristol-Myers Squibb Company operates in the Healthcare sector. The stock currently trades at $58.72 with a market capitalization of $104.2B. The stock has gained 12.8% over the past 52 weeks.
Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Leerink Partners's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Bristol-Myers Squibb Company
Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 05, 2026 | Leerink Partners | Market Perform | N/A |
| Sep 16, 2026 | Piper Sandler | Overweight | N/A |
| Sep 10, 2026 | HSBC | Hold | N/A |
| Aug 05, 2026 | Argus Research | Buy | N/A |
| Aug 03, 2026 | Citigroup | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View BMY Stock Page
Frequently Asked Questions
What does the Market Perform rating mean for BMY?
A rating of Market Perform from Leerink Partners reflects the analyst's outlook on Bristol-Myers Squibb Company (NYSE:BMY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BMY forecast page.
